FDA and Eli Lilly Evaluate Xigris for Bleeding Risk

February 11, 2009
The FDA is evaluating the safety of Eli Lilly’s sepsis treatment Xigris after a study showed an increased risk of serious bleeding and death in some patients taking the drug. The FDA is working with Lilly to evaluate the bleeding risks associated with the drug and will make its conclusions and recommendations public after the review, which may last several months, according to an FDA MedWatch.
Washington Drug Letter